| US 7,531,655 B2 | ||
| Large conductance calcium-activated K channel opener | ||
| Toshihiro Hosaka, Tokyo (Japan); Mari Kusama, Saitama (Japan); Kiyomi Ohba, Osaka (Japan); Rikako Kono, Saitama (Japan); and Shuntarou Kohnomi, Toda (Japan) | ||
| Assigned to Mitsubishi Tanabe Pharma Corporation, Osaka-Shi (Japan) | ||
| Appl. No. 10/531,330 PCT Filed Oct. 15, 2003, PCT No. PCT/JP03/13194 § 371(c)(1), (2), (4) Date Apr. 14, 2005, PCT Pub. No. WO2004/035570, PCT Pub. Date Apr. 29, 2004. |
||
| Claims priority of application No. 2002-300860 (JP), filed on Oct. 15, 2002; and application No. 2003-104260 (JP), filed on Apr. 08, 2003. | ||
| Prior Publication US 2006/0135597 A1, Jun. 22, 2006 | ||
| Int. Cl. C07D 409/14 (2006.01) | ||
| U.S. Cl. 544—333 [546/280.4] | 9 Claims |
1. A method for treatment of irritable bowel syndrome, chronic heart failure, angina, cardiac infarction, cerebral infarction,
pollakiuria, urinary incontinence, or, cerebral ischemia, which comprises administering an effective amount of a 5-membered
heterocyclic compound of the formula (I):
 wherein ring A is a ring represented by one of the formulae:
 R1 is a substituted or unsubstituted thiophene;
R2 is an alkyl substituted by carboxy; and
R3 is a substituted or unsubstituted pyridyl, a substituted or unsubstituted pyrimidinyl;
or a pharmaceutically acceptable salt thereof as an active ingredient.
|